Pfizer settles Celebrex antitrust class action for $94 million

Posted on: November 30th, 2017 by Steve Larson
Share

A class of direct purchasers who allege that Pfizer used fraudulent patents to delay generic competition for its anti-inflammatory drug Celebrex have reached a $94 million settlement agreement with Pfizer. In August, 2017, U.S. District Judge Arenda L. Wright Allen certified a class of 32 direct purchasers who claim Pfizer cost Celebrex buyers hundreds of millions of dollars by abusing the courts and the U.S. Patent and Trademark Office to extend its exclusive window to sell the drug.

The case is In re Celebrex (Celecoxib) Antitrust Litigation, case number 2:14-cv-00361, in the U.S. District Court for the Eastern District of Virginia.